Artwork
iconShare
 
Manage episode 520355008 series 1745677
Content provided by Srinivas Rao. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Srinivas Rao or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.
Dylan Beynon, founder of Mindbloom, shares the deeply personal story behind building the first at-home ketamine therapy platform. After losing his mother and sister to severe mental illness, Dylan became determined to bring psychedelic medicine into mainstream healthcare. He explains the neuroscience of how ketamine creates neuroplasticity—allowing the brain to rewire itself—and why these treatments are showing 10x better outcomes than SSRIs. From navigating FDA breakthrough therapy designations to dismantling decades of stigma from Nixon-era drug policy, Dylan reveals how Mindbloom is democratizing access to treatments that were once only available in $5,000 in-person clinics.

Hosted on Acast. See acast.com/privacy for more information.

  continue reading

1713 episodes